Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Significant Growth in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 123,800 shares, a growth of 56.5% from the August 15th total of 79,100 shares. Based on an average daily trading volume, of 240,200 shares, the short-interest ratio is presently 0.5 days. Currently, 24.5% of the shares of the company are sold short. Currently, 24.5% of the shares of the company are sold short. Based on an average daily trading volume, of 240,200 shares, the short-interest ratio is presently 0.5 days.

Salarius Pharmaceuticals Price Performance

NASDAQ:SLRX remained flat at $5.29 during mid-day trading on Monday. 2,843,280 shares of the company were exchanged, compared to its average volume of 161,855. The firm’s fifty day moving average price is $8.08 and its 200 day moving average price is $11.02. The stock has a market cap of $2.70 million, a price-to-earnings ratio of -0.12 and a beta of 0.51. Salarius Pharmaceuticals has a 1 year low of $4.50 and a 1 year high of $108.00.

Salarius Pharmaceuticals (NASDAQ:SLRX) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($33.00) by $32.55.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Salarius Pharmaceuticals to a “sell” rating in a research report on Friday, August 22nd.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.